文献速递糖尿病肥胖与代谢综合征

利拉鲁肽增加2型糖尿病患者含载脂蛋白B100脂蛋白的分解代谢并降低PCSK9表达

Liraglutide Increases the Catabolism of Apolipoprotein B100-Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression.
PubMed 文献 · Diabetes Care · 2021-02-02

该研究在10例2型糖尿病患者中采用稳定同位素动力学研究,评估利拉鲁肽(1.2 mg/天)治疗6个月前后含载脂蛋白B100脂蛋白的代谢变化,并在小鼠中评估相关基因表达。结果显示利拉鲁肽显著降低血浆载脂蛋白B100和空腹甘油三酯,加速VLDL1、VLDL2、IDL和LDL中载脂蛋白B100的分解代谢,并降低PCSK9等基因表达。

要点

  • 利拉鲁肽治疗6个月降低2型糖尿病患者血浆载脂蛋白B100和空腹甘油三酯。
  • 利拉鲁肽加速VLDL1、VLDL2、IDL和LDL中载脂蛋白B100的分解代谢。
  • 利拉鲁肽可能通过调节PCSK9等基因表达改善脂蛋白代谢。

核心结论

  • 利拉鲁肽治疗可显著加速2型糖尿病患者富含甘油三酯脂蛋白(VLDL1、VLDL2、IDL)和LDL的分解代谢。
  • 利拉鲁肽调节参与含载脂蛋白B100脂蛋白分解代谢的基因表达,可能降低2型糖尿病心血管风险。

研究设计与样本

  • 在10例2型糖尿病患者中进行体内稳定同位素(L-[1-13C]亮氨酸)动力学研究,比较利拉鲁肽(1.2 mg/天)治疗6个月前后的变化。
  • 在小鼠中评估利拉鲁肽对参与含载脂蛋白B100脂蛋白清除的基因表达的影响。
  • 体外实验评估利拉鲁肽对肝脏PCSK9表达的直接作用。

主要发现

  • 利拉鲁肽治疗显著降低血浆载脂蛋白B100(0.93 ± 0.13 vs. 1.09 ± 0.11 g/L,P = 0.011)和空腹甘油三酯(1.76 ± 0.37 vs. 2.48 ± 0.69 mmol/L,P = 0.005)。
  • 动力学研究显示VLDL1-载脂蛋白B100间接分解代谢显著增加(4.11 ± 1.91 vs. 2.96 ± 1.61 pools/day,P = 0.005)。
  • VLDL2-载脂蛋白B100间接分解代谢显著增加(5.17 ± 2.53 vs. 2.84 ± 1.65 pools/day,P = 0.008)。
  • IDL-载脂蛋白B100间接分解代谢显著增加(5.27 ± 2.77 vs. 3.74 ± 1.85 pools/day,P = 0.017)。
  • LDL-载脂蛋白B100分解代谢显著增加(0.72 ± 0.22 vs. 0.56 ± 0.22 pools/day,P = 0.005)。

临床怎么用

  • 对于2型糖尿病患者,利拉鲁肽治疗可能通过改善富含甘油三酯脂蛋白和LDL的分解代谢来降低心血管风险。
  • 利拉鲁肽对脂蛋白代谢的有益作用支持其在2型糖尿病合并血脂异常患者中的应用考虑。

局限性

  • 人体动力学研究样本量较小(10例患者)。
  • 动物和体外实验结果外推至人体需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Dyslipidemia observed in type 2 diabetes (T2D) is atherogenic. Important features of diabetic dyslipidemia are increased levels of triglyceride-rich lipoproteins and small dense LDL particles, which all have apolipoprotein B100 (apoB100) as a major apolipoprotein. This prompted us to study the effect of the GLP-1 agonist liraglutide on the metabolism of apoB100-containing lipoproteins. RESEARCH DESIGN AND METHODS: We performed an in vivo kinetic study with stable isotopes (L-[1-13C]leucine) in 10 patients with T2D before and after 6 months of treatment with liraglutide (1.2 mg/day). We also evaluated in mice the effect of liraglutide on the expression of genes involved in apoB100-containing lipoprotein clearance. RESULTS: In patients with T2D, liraglutide treatment significantly reduced plasma apoB100 (0.93 ± 0.13 vs. 1.09 ± 0.11 g/L, P = 0.011) and fasting triglycerides (1.76 ± 0.37 vs. 2.48 ± 0.69 mmol/L, P = 0.005). The kinetic study showed a significant increase in indirect catabolism of VLDL1-apoB100 (4.11 ± 1.91 vs. 2.96 ± 1.61 pools/day, P = 0.005), VLDL2-apoB100 (5.17 ± 2.53 vs. 2.84 ± 1.65 pools/day, P = 0.008), and IDL-apoB100 (5.27 ± 2.77 vs. 3.74 ± 1.85 pools/day, P = 0.017) and in catabolism of LDL-apoB100 (0.72 ± 0.22 vs. 0.56 ± 0.22 pools/day, P = 0.005). In mice, liraglutide increased lipoprotein lipase (LPL) gene expression and reduced proprotein convertase subtilisin/kexin type 9 (PCSK9), retinol-binding protein 4 (RBP4), and tumor necrosis factor-α (TNF-α) gene expression in adipose tissue and decreased PCSK9 mRNA and increased LDL receptor protein expression in liver. In vitro, liraglutide directly reduced the expression of PCSK9 in the liver. CONCLUSIONS: Treatment with liraglutide induces a significant acceleration of the catabolism of triglyceride-rich lipoproteins (VLDL1, VLDL2, IDL) and LDL. Liraglutide modifies the expression of genes involved in apoB100-containing lipoprotein catabolism. These positive effects on lipoprotein metabolism may reduce cardiovascular risk in T2D.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Vergès B, Duvillard L, Pais de Barros JP, et al. Liraglutide Increases the Catabolism of Apolipoprotein B100-Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression. Diabetes Care. 2021. PMID: 33531418. doi:10.2337/dc20-1843

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。